Mereo BioPharma Group plc 8-K

What Happened Mereo BioPharma Group plc filed a Form 8-K on March 27, 2026 (Item 5.02) reporting that Dr. Annalisa Jenkins informed the company on March 26, 2026 that she will not stand for re‑election to the Board at the 2026 annual general meeting of shareholders (the 2026 AGM), scheduled for May 14, 2026. Dr. Jenkins will continue to serve through the end of her current term, which expires immediately prior to the 2026 AGM. The filing states her decision was not due to any disagreement with the company or the Board.

Key Details

• Date of notice: March 26, 2026; Form 8‑K filed March 27, 2026.
• Affected director: Dr. Annalisa Jenkins; will not seek re‑election at the 2026 AGM (May 14, 2026).
• Term status: Will serve until her term expires immediately prior to the 2026 AGM.
• Company statement: Decision not to stand for re‑election was not the result of any disagreement with the company or Board. Document signed by General Counsel Charles Sermon.

Why It Matters A director choosing not to stand for re‑election is a governance update investors should note. The change may affect Board composition and any related committee assignments, and shareholders should watch for the company's announcement of nominees or replacements ahead of the May 14, 2026 AGM. The filing does not report any operational or financial impacts, and the company confirmed there were no disagreements prompting the departure.